Metraipolis › archive › dc_cd41c77231b6

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma — Europe PMC PMID:42494441

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42494441
DOI
10.3389/fmed.2026.1864843
License (as archived)
solo-consultazione
Archived
2026-10-18T13:40:37.506Z
SHA-256 of the archived text
da516d494fea3f5fd7e634344ee46029edf7692866a314b7e1a0c999b66a8930
Stable URL of this page
https://metraipolis.com/documento/dc_cd41c77231b6

How to cite

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma — Europe PMC PMID:42494441 — Europe PMC (en), https://europepmc.org/article/MED/42494441 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cd41c77231b6 (Metraipolis archive dc_cd41c77231b6, sha256 da516d494fea3f5fd7e634344ee46029edf7692866a314b7e1a0c999b66a8930)
BibTeX
@misc{dccd41c77231b6,
  title = {Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma — Europe PMC PMID:42494441},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42494441},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cd41c77231b6; sha256 da516d494fea3f5fd7e634344ee46029edf7692866a314b7e1a0c999b66a8930},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42494441. Agents can read the archived copy with the MCP tool read_document.